Bst2 Antibody Cat. No.: 4661

Availability: In stock

$0.00

 Price Options

* Required Fields

$0.00
psi-iconSpecifications
HOST SPECIES:Rabbit
SPECIES REACTIVITY: Human, Mouse
HOMOLOGY: Predicted species reactivity based on immunogen sequence: Rat: (83%)
IMMUNOGEN: Bst2 antibody was raised against a 18 amino acid synthetic peptide near the amino terminus of the mouse Bst2.

The immunogen is located within amino acids 60 - 110 of Bst2.
TESTED APPLICATIONS: ELISA, WB
APPLICATIONS: Bst2 antibody can be used for detection of Bst2 by Western blot at 1 - 2 μg/mL.

Antibody validated: Western Blot in human samples. All other applications and species not yet tested.
POSITIVE CONTROL:1) Cat. No. 1224 - Daudi Cell Lysate

psi-iconProperties
PURIFICATION:Bst2 Antibody is affinity chromatography purified via peptide column.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated
PHYSICAL STATE:Liquid
BUFFER:Bst2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:Bst2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

psi-iconAdditional Info
OFFICIAL SYMBOL:Bst2
ALTERNATE NAMES:Bst2 Antibody: GREG, Bst-2, CD317, C87040, DAMP-1, 2310015I10Rik, Bone marrow stromal antigen 2, BST-2
ACCESSION NO.:AAH87949
PROTEIN GI NO.:56971124
GENE ID:69550
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:Bst2 Antibody: Bst2 was first identified as a novel terminal B-cell-restricted antigen termed HM1.24 that is expressed on certain bone marrow cells as well as other tissues. The surface expression of Bst2 on fibroblast cell lines facilitated the stromal cell-dependent growth of DW34, a pre-B-cell line, suggesting that this protein is involved in pre-B-cell growth. Later experiments also showed it to be upregulated in several myeloma cells. More recently, Bst2 was identified an inhibitor of retroviral release from human cells whose activity is antagonized by the HIV-1 accessory protein Vpu. While Bst2 caused retention of virions on cell surfaces or endocytosis into Bst2-positive compartments, its depletion abolished the viral requirement for Vpu for virus release. This activity may represent a potential therapeutic strategy for the treatment of HIV/AIDS.
REFERENCES:1) Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood1994; 84:1922-30.
2) Ishikawa J, Kaisho T, Tomizawa H, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics1995; 26:527-34.
3) Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun.1999; 258:583-91.
4) Neil SJ, Zang T, and Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature2008; 451:425-30.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.